SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

INKT

MiNK Therapeutics
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The survival and immune reprogramming data may reframe clinical development strategy around sequencing and durability rather than response rate. Traders should monitor for upcoming trial expansions, partnership announcements, or FDA guidance on trial design for accelerated approval pathways.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.21
T+0 close · Apr 17, 2026 · via day close
Latest settled
−19.70%
T+60 · $11.41
Vs SPY
−25.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $14.21entry
  2. T+1 · 7mo ago −9.78%α −9.59% · $12.82
  3. T+5 · 7mo ago −22.94%α −23.50% · $10.95
  4. T+20 · 6mo ago −26.04%α −31.41% · $10.51
  5. T+60 · 4mo ago −19.70%α −25.85% · $11.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combination with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer, showing a 77% disease control rate and improved survival with an induction strategy. Despite missing the primary endpoint of ORR, the durable responses and immune activation support further development. The data are being presented at AACR 2026.

Key Facts

  • Phase II trial (n=17) showed 77% disease control rate (DCR) in PD-1 refractory gastroesophageal cancer patients.
  • Induction strategy with agenT-797 led to median PFS of 6.9 months vs. 3.5 months (HR 0.19; p=0.015) and median OS of 9.5 vs. 5.2 months.
  • 43% of induction-treated patients were alive at 12 and 18 months, compared to 20% and 0% in non-induction cohort.
  • Trial did not meet primary endpoint of ORR, but durable disease control and survival are emphasized as key benefits.
  • Biomarker analyses show immune activation, T-cell infiltration, and tertiary lymphoid structure formation.

Financial Impact

High clinical significance despite small sample size; potential to accelerate development and attract partnerships.

valuationpipeline valuepartnership potential

Risk Factors

  • Small trial size (n=17) limits statistical power and generalizability.
  • Primary endpoint (ORR) not met, which may raise skepticism among some investors.
  • Safety profile includes immune-related adverse events such as colitis and hepatitis.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276455

Track record

21 reports on INKT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026